The news is by your side.


GSK, Pfizer to merge consumer healthcare units

LONDON: Pharmaceutical giants GlaxoSmithKline and Pfizer on Wednesday announced a merger of their consumer healthcare units that produce over-the-counter medicines. GSK said it would have a 68-percent controlling equity interest in the joint venture that will have combined sales of about £9.8 billion ($12.7 billion, 10.9 billion euros). The deal paves the way for British group GSK to have two UK-listed companies, one specialised in the development of drugs and the other in consumer healthcare. It comes as the…

GSK ‘real world’ drug test has second success in asthma

LONDON: GlaxoSmithKline notched up a second win for its pioneering "real world" approach to testing new drugs on Friday as its inhaled medicine Breo proved significantly better than standard care in helping people with asthma. The success of the 4,233-patient trial, which tested Breo in day-to-day practice across the town of Salford in northern England, follows a similar win for the medicine in chronic obstructive pulmonary disease (COPD) a year ago. The study showed the drug, which is marketed as Relvar in Europe, was…

Gilead challenges GSK with strong HIV drug data

SEATTLE: Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir. Gilead's bictegravir, another so-called integrase inhibitor drug, delivered 97 percent virus suppression, making it just as effective as GSK's product, data presented at a medical meeting in Seattle late on Monday showed. Importantly, there were no cases of resistance emerging to the new medicine in the 98-patient…